Elevar Therapeutics to Present Three Abstracts at ESMO 2026, Including Phase 2 THRIVE Trial of Rivoceranib in Thymic Tumors
核心洞察
Elevar Therapeutics (搜索) announced three abstracts accepted for presentation at the ESMO Congress 2026 in Madrid, October 23–27.
A rapid oral presentation will feature Phase 2 results from the KCSG LU23-09 (THRIVE) trial of rivoceranib in pretreated metastatic thymic epithelial tumors (搜索).
A poster sub-analysis of the CARES-310 study will examine how early antibiotic exposure affects camrelizumab plus rivoceranib efficacy in unresectable hepatocellular carcinoma (搜索).
Elevar Therapeutics (搜索), a majority-owned subsidiary of HLB Co., Ltd. (搜索), will showcase clinical progress across its oncology pipeline with three abstract presentations at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23–27 in Madrid, the company announced on July 27, 2026.
The presentations span three distinct programs: rivoceranib as monotherapy in thymic epithelial tumors (搜索), the combination of camrelizumab plus rivoceranib in hepatocellular carcinoma, and lirafugratinib, an FGFR2 (搜索) inhibitor, with a focus on treatment-related adverse events.
Rivoceranib in Thymic Epithelial Tumors (搜索): The THRIVE Trial
The most prominent presentation is a rapid oral session featuring Phase 2 results of rivoceranib in patients with pretreated metastatic thymic epithelial tumors (搜索). The multi-center KCSG LU23-09 (THRIVE) trial will be presented by Sehhoon Park, M.D., Ph.D., Professor and Thoracic Medical Oncologist at Samsung Medical Center in Seoul, South Korea.
The presentation (No. 4155RO) is scheduled for October 26, 2026, from 10:15 a.m. to 11:45 a.m. CET in the Burgos Auditorium – Hall 3, as part of the session on non-metastatic NSCLC and other thoracic malignancies. Thymic epithelial tumors (搜索) represent a rare form of thoracic malignancy with limited therapeutic options, particularly in the metastatic, pretreated setting.
CARES-310 Sub-Analysis: Antibiotic Exposure and Immunotherapy Efficacy
A poster presentation (No. 1686P) will explore the impact of early antibiotic exposure on the efficacy of camrelizumab plus rivoceranib compared with sorafenib in patients with unresectable hepatocellular carcinoma (搜索) (uHCC). This sub-analysis of the CARES-310 study addresses the clinically relevant question of how concomitant antibiotic use may modulate responses to immunotherapy-based combinations in HCC.
The poster will be presented on October 25, 2026, from 12:00 p.m. to 12:45 p.m. CET under the hepatocellular carcinoma topic.
ReFocus Trial: Immune Checkpoint Inhibitors and Mucocutaneous Adverse Events
An ePoster (No. 1096eP) will feature a post-hoc analysis from the ReFocus trial examining the relationship between prior immune checkpoint inhibitor (ICI) exposure and the risk of mucocutaneous adverse events (mcAEs) associated with lirafugratinib, an FGFR2 (搜索) inhibitor. This analysis falls under the developmental therapeutics topic and will be available via searchable screens in Hall 5 throughout the congress.
Elevar Therapeutics (搜索), based in Fort Lee, New Jersey, is a fully integrated biopharmaceutical company focused on developing medicines for patients with limited or inadequate therapeutic options, with expertise rooted in oncology.